Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis
- 139 Downloads
Requirement for hospitalization in ulcerative colitis (UC) is a marker of severity of disease. However, the paradigm of when to escalate therapy in such patients and the benefits of early immunomodulator initiation is less well established.
To examine the benefits of early therapy escalation in immunosuppression-naïve patients hospitalized with severe ulcerative colitis responsive to steroids.
We identified hospitalized UC patients who were immunosuppression naïve at index hospitalization and responded to intravenous steroids, not requiring medical or surgical rescue therapy. The ‘therapy escalated’ group comprised of those who were initiated on immunomodulators within 3 months of hospitalization. The need for colectomy at 12 months was compared to the ‘not escalated’ group who remained on non-immunosuppressive therapy.
Among 133 immunosuppressive naïve patients hospitalized for ulcerative colitis, 13 (9.8%) who responded to intravenous steroids and did not require rescue therapy underwent colectomy by 1 year. Among 123 patients who escalated to either immunomodulators (n = 46, 37%) or remained on non-immunosuppressive therapy (92% on 5-ASA), there was no difference in the need for colectomy at 1 year (10.8 vs. 7.8%; multivariate OR 1.29, 95% CI 0.35–4.74). There was also no difference in the time to colectomy between the two groups (p = 0.55).
Immunosuppression-naïve ASUC patients who respond to intravenous steroids remain at risk for colectomy. Immunomodulator initiation by 3 months did not reduce risk of colectomy at 1 year. There is an important need for prospective studies identifying thresholds for therapy escalation in UC.
KeywordsHospitalization Colectomy Steroids Acute severe ulcerative colitis
AV contributed to study design, data extraction and statistical analysis, drafting of the manuscript, and approval of the final manuscript. LX extracted the data and approved the final manuscript. JL, JJG, FC, HK approved the final manuscript. ANA was involved in study design and supervision, statistical analysis, drafting of the manuscript, and approval of the final manuscript.
Ananthakrishnan is supported in part by grants from the National Institutes of Health (R03 DK112909) and the Crohn’s and Colitis Foundation.
Compliance with ethical standards
Conflict of interest
Ananthakrishnan has served on scientific advisory boards for Abbvie, Takeda, Gilead, and Merck and has received research support from Pfizer.
- 10.Sandborn W, van Assche G, Reinisch W. Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results. Gastroenterol Hepatol (N Y). 2013;9:317–320.Google Scholar
- 21.Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a Research Patient Data Repository. In: AMIA Annual Symposium Proceedings AMIA Symposium; 2006:1044.Google Scholar
- 27.Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Ind J Gastroenterol. 2003;22:79–81.Google Scholar